TEVA-LISINOPRIL/HCTZ (TYPE P) TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

LISINOPRIL (LISINOPRIL DIHYDRATE); HYDROCHLOROTHIAZIDE

Inapatikana kutoka:

TEVA CANADA LIMITED

ATC kanuni:

C09BA03

INN (Jina la Kimataifa):

LISINOPRIL AND DIURETICS

Kipimo:

10MG; 12.5MG

Dawa fomu:

TABLET

Tungo:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG; HYDROCHLOROTHIAZIDE 12.5MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

30/100

Dawa ya aina:

Prescription

Eneo la matibabu:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0222417003; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2010-12-08

Tabia za bidhaa

PRODUCT MONOGRAPH
PR
TEVA-LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin Converting Enzyme Inhibitor/Diuretic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Control No: 169889
Date of Preparation:
November 26, 2010
Date of Revision:
January 21, 2014
TEVA-LISINOPRIL/HCTZ (TYPE P) Tablets
2
PRODUCT MONOGRAPH
Pr
TEVA-LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin-Converting Enzyme Inhibitor/Diuretic
ACTION AND CLINICAL PHARMACOLOGY
TEVA-LISINOPRIL/HCTZ (TYPE P) (lisinopril and hydrochlorothiazide
tablets) combines the
action of an angiotensin-converting enzyme (ACE) inhibitor,
lisinopril, and a diuretic,
hydrochlorothiazide.
LISINOPRIL
Angiotensin-converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion
of angiotensin I to the pressor substance, angiotensin II. Inhibition
of ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum potassium. In patients
treated with lisinopril plus a
thiazide diuretic, there was essentially no change in serum potassium
(see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system,
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
PHARMACODYNAMICS
LISINOPRIL
Administration of lisinopril to patients with hypertension results in
a reduction of both supine
and standing blood pressure. Abrupt withdrawal of li